Ono Pharmaceutical xa daim ntawv thov kev qhia tshiab ntawm ONOACT hauv Nyiv

Ono Pharma tsis ntev los no tau tshaj tawm tias nws tau xa daim ntawv thov hauv Nyij Pooj rau ONOACT cov tshuaj intravenous infusion ntawm 50mg / 150mg (landiolol hydrochloride), luv luv-acting selective β1 receptor blocker rau kev hloov kho ntxiv Cov tsos mob: Siv rau cov menyuam yaus uas muaj lub plawv tsis ua haujlwm los kho tachyarrhythmias ( supraventricular tachycardia, atrial fibrillation, atrial flutter)

Hauv cov neeg mob menyuam yaus, yog tias muaj lub plawv tsis ua haujlwm thiab hemodynamic instability, xws li kab mob hauv lub plawv tom qab qhib lub plawv, yog tias tachyarrhythmia tseem nyob, nws yuav ua rau mob hnyav lossis tuag taus. Yog li ntawd, tachyarrhythmia yuav tsum tau kho tam sim ntawd. Txij li thaum tsis siv tshuaj kho mob xws li catheter ablation tej zaum yuav nyuaj rau cov neeg mob me, nyob ntawm tus neeg mob' lub cev thiab hnub nyoog, kev kho tshuaj yog ib qho tseem ceeb thiab txoj kev kho mob tseem ceeb. Txawm li cas los xij, Nyiv muaj ob peb cov tshuaj tiv thaiv arrhythmic pom zoo rau cov kev qhia rau menyuam yaus, thiab cov kev kho mob kuj raug txwv. Yog li ntawd, yuav tsum muaj txoj kev npaj kho mob tshiab hauv pab pawg neeg mob no.

ONOACT yog ib qho luv luv-acting xaiv β1 receptor blocker, uas txo lub plawv dhia los ntawm kev xaiv thaiv β1 receptors feem ntau tam sim no hauv plawv. ONOACT tau pom zoo rau kev kho mob ntawm tachyarrhythmias hauv cov neeg laus uas muaj lub plawv tsis ua haujlwm.

ONOACT-Landilol Hydrochloride

Daim ntawv thov ONOACT rau menyuam yaus yog ua raws li cov txiaj ntsig ntawm ntau lub chaw, qhib-daim ntawv sau npe, ib sab caj npab, theem 2/3 kev tshawb fawb soj ntsuam (ONO-1101-31) hauv cov menyuam yaus uas muaj tachyarrhythmia nrog lub plawv tsis ua haujlwm. Cov ntaub ntawv qhia tau hais tias ONOACT tuaj yeem txo lub plawv dhia sai yam tsis muaj kev txo lub plawv dhia. Yog li, ONOACT xav kom pab kho tachyarrhythmia hauv cov menyuam yaus uas muaj lub plawv tsis ua haujlwm.

Ono Pharmaceutical tau txais kev pom zoo los ntawm ONOACT los ntawm Nyij Pooj lub koom haum tswj hwm hauv Lub Xya Hli 2002 rau kev kho mob xwm txheej ceev ntawm cov neeg laus cov neeg mob uas muaj cov kab mob tachyarrhythmias (atrial fibrillation, atrial flutter, sinus tachycardia), thiab nyob rau lub Cuaj Hli 2002 Marketed rau qhov kev qhia no.

Tom qab ntawd, Ono Pharmaceutical tau txais kev pom zoo rau cov lus qhia ntxiv hauv qab no rau cov neeg laus cov neeg laus: (1) Kev kho mob xwm txheej ceev ntawm postoperative tachyarrhythmias (atrial fibrillation, atrial flutter, sinus tachycardia) uas tshwm sim nyob rau hauv circulatory dynamics xyuas (2006) Lub kaum hli ntuj); (2) Tachyarrhythmias nrog lub plawv tsis ua haujlwm (atrial fibrillation thiab atrial flutter) (Lub Kaum Ib Hlis 2013); (3) Kev phom sij rau lub neej refractory arrhythmias (ventricular fibrillation thiab ntshav Rheologically unstable ventricular tachycardia) (Lub Peb Hlis 2019); (4) Sepsis-related tachyarrhythmias (atrial fibrillation, atrial flutter, sinus tachycardia) (Lub Rau Hli 2020).